免疫检查点抑制剂相关心血管毒性:国际心脏肿瘤学会立场声明
该立场声明由国际心脏肿瘤学会联合肿瘤学、血液学和心脏病学专家制定,聚焦ICI治疗相关心血管毒性,尤其是心肌炎。声明指出心肌炎仍是最受关注的不良反应,但致死率随时间下降且表现谱系扩大;管理推荐因严重程度而异,多学科协作对急性毒性处理和后续癌症治疗决策(包括ICI再挑战)至关重要。
要点
- ICI相关心血管毒性包括心肌炎、心包炎、血管炎及动脉粥样硬化加重所致急性缺血事件。
- 心肌炎表现从意义不明的肌钙蛋白升高到暴发性心肌炎不等,致死率已随时间下降。
- 管理推荐因严重程度而异,多学科协作是处理急性毒性和ICI再挑战决策的关键。
核心结论
- 心肌炎仍是ICI治疗患者心血管毒性谱中最受关注的不良反应,但致死率已随时间下降且表现谱系扩大。
- ICI相关心血管毒性管理推荐因严重程度而异,多学科协作对急性毒性处理和后续癌症治疗决策(包括ICI再挑战)至关重要。
研究设计与样本
- 国际心脏肿瘤学会立场声明,由肿瘤学、血液学和心脏病学专家代表共同参与制定。
主要发现
- ICI相关心血管毒性包括炎症相关疾病如心肌炎、心包炎和血管炎,以及慢性炎症状态加重如动脉粥样硬化伴急性缺血并发症(心肌梗死和卒中)。
- 接受ICI治疗的患者还可出现心脏功能障碍、应激性心肌病(Takotsubo或心尖球囊样综合征)和无心肌炎症细胞浸润的心力衰竭。
- 在全身炎症环境、心肌炎或缺血背景下可出现房性和室性心律失常。
- 心肌炎表现谱系从意义不明的肌钙蛋白升高到冒烟型、非严重型和严重或暴发性心肌炎,致死率已随时间下降。
临床怎么用
- 对接受ICI治疗的患者应警惕心血管毒性,尤其心肌炎,并根据严重程度采取相应管理推荐。
- 缺血性心脏病是这些患者的主要鉴别诊断,心包炎可同时存在,房性和室性心律失常也可使临床情况复杂化。
- 多学科协作应贯穿急性毒性处理及后续癌症治疗决策,包括ICI再挑战的评估。
局限性
- 声明识别出若干知识空白,需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The introduction of immune checkpoint inhibitor (ICI) therapy has improved cancer outcomes but at the cost of adverse events, mainly related to the immune system. Cardiovascular (CV) toxic effects, and especially myocarditis, are of particular concern and are the subject of this position statement by the International Cardio-Oncology Society with representation of experts from oncology, hematology, and cardiology. OBSERVATIONS: CV toxic effects of ICI therapies include inflammation-associated diseases, such as myocarditis, pericarditis, and vasculitis, as well as the aggravation of chronic inflammatory conditions, such as atherosclerosis with acute ischemic complications (myocardial infarction and stroke). Patients taking ICI therapies can also develop cardiac dysfunction, stress-induced cardiomyopathy (Takotsubo or apical ballooning syndrome), and heart failure without inflammatory cell infiltration of the myocardium. Atrial and ventricular arrhythmias can emerge in the setting of a systemic inflammatory milieu, myocarditis, or ischemia. Of all potential CV adverse effects, myocarditis remains of highest concern, although fatality rates have declined over time with a broadening spectrum of presentations ranging from troponin elevation of uncertain significance to smoldering, nonsevere, and severe or fulminant myocarditis. CONCLUSIONS AND RELEVANCE: Concerns for myocarditis continue to dominate the spectrum of CV toxic effects in patients receiving ICI therapy. Recommendations for management vary according to severity. Multidisciplinary collaborations remain key for managing acute toxic effects and future cancer treatment decisions, including ICI rechallenge. Ischemic heart disease constitutes the main differential diagnosis in these patients, while pericarditis can be concomitantly present, and atrial and ventricular arrhythmias can also complicate the clinical picture. Several gaps in knowledge are identified and require further research.
引用
- Herrmann J, Barac A, Carver J, et al. Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement. JAMA Oncol. 2026. PMID: 41231466. doi:10.1001/jamaoncol.2025.4543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。